ReForm Biologics appoints Jim Sherblom to its Board of Directors as Chairman

– USA, MA –  ReForm Biologics today announced the appointment of Jim Sherblom to its board of directors as chairman to lead the shift in a strategy aiming to expand its focus to develop a new generation of bio-innovative biologic medicines in-house to improve patient access, safety, and convenience.

ReForm will develop a bio-innovative medicine pipeline to convert hospital-based intravenous dosing to subcutaneous injections on an outpatient basis. ReForm will manage therapeutic viscosity to reduce injection volumes and fluid injection force, greatly enhancing many therapeutics, including pediatric applications. This strategy will seek to improve patient compliance, convenience, flexibility, and could ultimately reduce patient pain and suffering.

“Jim Sherblom, a seasoned executive in the pharmaceutical healthcare industry, brings years of experience to ReForm in building blue chip pharmaceutical and biotechnology companies,” said CEO, Dr. John M. Sorvillo. “Jim was the founding CFO of Genzyme, which he took public, as well as the founding CEO of Transgenic Sciences Inc., which he also took public and later sold to Genzyme. In addition, he founded Seaflower Ventures and was a founding member of the Massachusetts Biotechnology Council. On behalf of all of us at ReForm, we welcome Jim to our board of directors.”

“Better patient care has always been the dream of the biotechnology sector. Building on nearly four decades of scientific advances, we are now on the cusp of introducing better biologic medicines that will enhance patient access to these transformative therapies,” said newly appointed Board Chairman, Jim Sherblom. “I am delighted to join the team at ReForm to help lead this revolution in better patient care and improved clinical outcomes.”

About ReForm Biologics

ReForm Biologics creates gentler therapies for fragile patients, including pediatric patients, by using our proprietary technology to transform intravenous drugs into subcutaneous injections, to reduce adverse reactions, and to improve drug stability. Our goal is to enhance comfort, convenience, safety, and compliance so that patients living with debilitating diseases can experience a better life while treating their medical conditions.

For more information: https://reformbiologics.com/

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.